Effects of Dehydration on Neuromuscular Performance and Sympathetic Control of Cardiovascular Function
Keywords
Abstract
Description
Study Objectives and Hypotheses
Primary Objective
The primary objectives of this study are to understand the in vivo effects of dehydration on:
1. Sympathetic neural control of cardiovascular function (MSNA), and
2. Neuromuscular function (CAC) via the IT Test
The primary hypotheses of this study are:
1. Baseline MSNA, and MSNA responses to tilt, will be higher in response to extracellular dehydration due to larger intravascular volume losses and greater baroreceptor unloading.
2. Neuromuscular function (CAC) via the IT Test will a) be more impaired by intracellular dehydration (cell stress) and b) CAC will show a greater performance reduction than CAR because it reduces the emphasis placed on the voluntary portion of performance (i.e., MVC).
Ancillary Questions/Sub Studies
1. The collection of blood and urine before and after exercise-heat stress and dehydration provides an opportunity to measure and characterize cytokine and intestinal barrier integrity marker (I-FAB, claudin-3) responses (blood) and renal stress biomarkers (urine) in humans. This descriptive research 'sub-study' directly complements Task Area T10 (Hot Weather Operations and Hydration: Injury and Performance Optimization) near and mid-term research goals of identifying biomarkers of heat stress for protection against heat injury. There are no hypotheses associated with this sub-study.
2. The study of dehydration requires rehydration for recovery. Rehydration provides an opportunity for a novel comparison of renal water retention (urine volume) when consuming equal volumes of two different commercial beverages (Gatorade® or Enterade-S®). Unlike Gatorade®, which is a carbohydrate-based beverage containing electrolytes, Enterade-S® is an amino acid-based beverage containing electrolytes. We hypothesize that the unique formulation of Enterade-S® will improve the rate of fluid absorption and fluid retention compared to Gatorade® in both intracellular and extracellular dehydration trials.
Dates
| Last Verified: | 03/31/2020 |
| First Submitted: | 08/22/2017 |
| Estimated Enrollment Submitted: | 08/22/2017 |
| First Posted: | 08/27/2017 |
| Last Update Submitted: | 04/19/2020 |
| Last Update Posted: | 04/21/2020 |
| Actual Study Start Date: | 10/30/2014 |
| Estimated Primary Completion Date: | 12/07/2016 |
| Estimated Study Completion Date: | 11/30/2017 |
Condition or disease
Intervention/treatment
Other: Gatorade or Enterade
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Exercise heat STress (EHS) EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies. | |
| Experimental: Lasix (LAS) LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Male or female, age 18-45 - In good health as determined by OMSO General Medical Clearance - Passed his/her most recent Army Physical Fitness Test (APFT) (military volunteers only) or exercise at least 2 times per week (civilian volunteers) - Ability to comprehend and willingness to sign informed consent Exclusion Criteria: - Females who are pregnant or planning to become pregnant during the study - Taking prescription or over the counter medication, other than a contraceptive (unless approved by OMSO and PI) - Physical problems/injuries associated with walking or cycling - Allergy to sulfa drugs (Lasix™ or sulfonamide antibiotics such as Septra™) - Allergy to skin adhesive - Hemoglobinopathy (sickle cell trait) - Heart, lung, kidney, muscle, or nerve disorder(s) - History of heat or orthostatic intolerance - Diagnosed and/or treated for fluid/electrolyte imbalance within the last 30 days - Presence of metal implants/electronic medical devices in lower extremities - Current or previous (within the past 5 years) diagnosis of any autonomic disorder, including idiopathic orthostatic intolerance, orthostatic hypotension, postural tachycardia syndrome (POTS), or neurocardiogenic syncope (MSNA group only) - Tobacco/nicotine use (MSNA group only) - Significant muscle, joint, or bone injury affecting the legs within the last 6 months (CAC group only) - Difficulty swallowing large pills - History of obstructive disease of the gastrointestinal tract including (but not limited to) diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis; or previous gastrointestinal surgery. |
Outcome
Primary Outcome Measures
1. Water and electrolyte retention [180 minutes]
Secondary Outcome Measures
1. Body water compartment changes [180 minutes]
